These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15861009)

  • 81. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
    Hayashidani S; Tsutsui H; Shiomi T; Suematsu N; Kinugawa S; Ide T; Wen J; Takeshita A
    Circulation; 2002 Feb; 105(7):868-73. PubMed ID: 11854129
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Contributory role of matrix metalloproteinases in cardiovascular remodeling.
    Gunasinghe SK; Ikonomidis J; Spinale FG
    Curr Drug Targets Cardiovasc Haematol Disord; 2001 Dec; 1(2):75-91. PubMed ID: 12769658
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Using proteomics to uncover extracellular matrix interactions during cardiac remodeling.
    Patterson NL; Iyer RP; de Castro Brás LE; Li Y; Andrews TG; Aune GJ; Lange RA; Lindsey ML
    Proteomics Clin Appl; 2013 Aug; 7(7-8):516-27. PubMed ID: 23532927
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Myocardial infarction remodeling that progresses to heart failure: a signaling misunderstanding.
    Mouton AJ; Rivera OJ; Lindsey ML
    Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H71-H79. PubMed ID: 29600895
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Matrix metalloproteinase therapy in heart failure.
    Spinale FG; Wilbur NM
    Curr Treat Options Cardiovasc Med; 2009 Aug; 11(4):339-46. PubMed ID: 19627666
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions.
    Jacob MP
    Biomed Pharmacother; 2003; 57(5-6):195-202. PubMed ID: 12888254
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes.
    Bhalla V; Georgiopoulou VV; Azeem AA; Marti CN; Cole RT; Laskar SR; De Staercke C; Hooper WC; Smith AL; Kalogeropoulos AP; Butler J
    Int J Cardiol; 2011 Sep; 151(2):237-9. PubMed ID: 21723628
    [No Abstract]   [Full Text] [Related]  

  • 88. Extracellular matrix roles during cardiac repair.
    Jourdan-Lesaux C; Zhang J; Lindsey ML
    Life Sci; 2010 Sep; 87(13-14):391-400. PubMed ID: 20670633
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Emerging therapeutic targets in chronic heart failure: part II.
    Roenicke V; Leclair S; Hoffmann A; Becker M; Szado T; Kirsch T; Stoss O; Navé BT; Henkel T
    Expert Opin Ther Targets; 2003 Feb; 7(1):49-59. PubMed ID: 12556202
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Invited for debate: is there a virus-specific matrix destruction in the course of disease in dilated cardiomyopathy?
    Waagstein F
    Ernst Schering Res Found Workshop; 2006; (55):251-7. PubMed ID: 16329666
    [No Abstract]   [Full Text] [Related]  

  • 91. Cardiac remodeling induced by smoking: concepts, relevance, and potential mechanisms.
    Minicucci MF; Azevedo PS; Polegato BF; Paiva SA; Zornoff LA
    Inflamm Allergy Drug Targets; 2012 Dec; 11(6):442-7. PubMed ID: 22680625
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Response to letter regarding article, "Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume".
    Miller CA; Naish JH; Bishop P; Coutts G; Clark D; Zhao S; Ray SG; Yonan N; Williams SG; Flett AS; Moon JC; Greiser A; Parker GJ; Schmitt M
    Circ Cardiovasc Imaging; 2013 Jul; 6(4):e26-7. PubMed ID: 23861457
    [No Abstract]   [Full Text] [Related]  

  • 93. Amplified bioactive signaling and proteolytic enzymes following ischemia reperfusion and aging: remodeling pathways that are not like a fine wine.
    Spinale FG
    Circulation; 2010 Jul; 122(4):322-4. PubMed ID: 20625106
    [No Abstract]   [Full Text] [Related]  

  • 94. Recombinant Tissue Inhibitor Subdues Matrix Metalloproteinases and Produces Novel Images With New Possibilities.
    Schelbert HR
    Circ Cardiovasc Imaging; 2019 Nov; 12(11):e009915. PubMed ID: 31707812
    [No Abstract]   [Full Text] [Related]  

  • 95. Myocardial remodeling, an overview.
    Cokkinos DV; Pantos C
    Heart Fail Rev; 2011 Jan; 16(1):1-4. PubMed ID: 20872278
    [No Abstract]   [Full Text] [Related]  

  • 96. Immune Cells in Cardiac Injury Repair and Remodeling.
    Zambrano MA; Alcaide P
    Curr Cardiol Rep; 2023 May; 25(5):315-323. PubMed ID: 36961658
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Insights into left ventricular remodeling through noninvasive measures of myocardial matrix expansion with cardiovascular magnetic resonance.
    Di Carli MF; Kwong RY; Jerosch-Herold M
    Circulation; 2012 Sep; 126(10):1179-81. PubMed ID: 22949538
    [No Abstract]   [Full Text] [Related]  

  • 98. Age-related myocardial remodeling: myth or reality?
    Pudil R
    Vnitr Lek; 2020; 66(8):507-511. PubMed ID: 33740851
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical and Molecular Implications of Osteopontin in Heart Failure.
    Mamazhakypov A; Sartmyrzaeva M; Sarybaev AS; Schermuly R; Sydykov A
    Curr Issues Mol Biol; 2022 Aug; 44(8):3573-3597. PubMed ID: 36005141
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.